CNS Pharmaceuticals Corp - CNSP Net Assets per Single Share

Public company logo of CNS Pharmaceuticals Inc (CNSP)

The GURU.Markets terminal provides the book value per share trend, where 12.35 indicates the value of this parameter. CNS Pharmaceuticals (CNSP) is accelerating the market launch of Berubicin through partnerships with Western clinics. Targeted drug development in the US is focused on overcoming the blood-brain barrier. The company is currently in the research stage with no current revenue, relying on the issuance of securities.

CNS Pharmaceuticals Inc (CNSP) - Accounting Value per Share from 07/04/2022 to 10/28/2026

Summary analytical data breakdowns for cnspharma.com (CNSP)

- price and consensus price forecast:
Price Chart CNS Pharma|CNSP - Analyst Median Target
- market capitalization data:
Market Value CNS Pharmaceuticals, Inc.|CNSP - Full Business Value
- book capitalization data:
Book Value per Share CNS Pharmaceuticals|CNSP - Company Net Assets|Market Capitalization to Book Value Ratio cnspharma.com|CNSP - Company Total Assets
- debt and liquidity data:
Debt to Equity CNS Pharmaceuticals|CNSP - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital CNS Pharmaceuticals, Inc.|CNSP - Company Total Debt|Debts to Book Capitalization CNS Pharmaceuticals, Inc.|CNSP - Long-Term Debt|Company Short-Term Debt CNS Pharmaceuticals
Analysis of all company metrics:CNS Pharma, CNSP
Manufactured product of cnspharma.com

Developing monopoly drugs for the treatment of brain cancer requires colossal capital expenditures, which directly form the net asset base of CNS Pharmaceuticals (CNSP). The book value per share trend reflects the difference between all assets and liabilities per share, allowing investors to assess the real value of CNS Pharmaceuticals (CNSP) without accounting for market speculation and price volatility.

Competitor analysis for CNS Pharmaceuticals

Net Assets per Single Share SHPH (Shuttle Pharma)